PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
13.78%
Revenue growth under 50% of VET's 48.79%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
12.45%
Gross profit growth under 50% of VET's 60.79%. Michael Burry would be concerned about a severe competitive disadvantage.
12.10%
EBIT growth below 50% of VET's 109.92%. Michael Burry would suspect deeper competitive or cost structure issues.
12.10%
Operating income growth under 50% of VET's 109.92%. Michael Burry would be concerned about deeper cost or sales issues.
1213.67%
Net income growth above 1.5x VET's 290.48%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
1258.33%
EPS growth above 1.5x VET's 286.84%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
1258.33%
Diluted EPS growth above 1.5x VET's 289.19%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-2.45%
Share reduction while VET is at 1.95%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-2.76%
Reduced diluted shares while VET is at 1.41%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
2.63%
Dividend growth above 1.5x VET's 0.78%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
13.66%
OCF growth 1.25-1.5x VET's 11.81%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
99.94%
FCF growth 1.25-1.5x VET's 83.67%. Bruce Berkowitz would see if capex decisions or cost controls create a cash flow advantage.
409.86%
10Y revenue/share CAGR under 50% of VET's 2003.92%. Michael Burry would suspect a lasting competitive disadvantage.
436.60%
5Y revenue/share CAGR above 1.5x VET's 248.76%. David Dodd would look for consistent product or market expansions fueling outperformance.
137.17%
3Y revenue/share CAGR at 75-90% of VET's 156.57%. Bill Ackman would expect new product strategies to close the gap.
438.60%
10Y OCF/share CAGR under 50% of VET's 1786.72%. Michael Burry would worry about a persistent underperformance in cash creation.
180.64%
5Y OCF/share CAGR at 50-75% of VET's 265.44%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
164.29%
3Y OCF/share CAGR at 50-75% of VET's 238.50%. Martin Whitman would suspect weaker recent execution or product competitiveness.
398.91%
Below 50% of VET's 7235.09%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
170.66%
5Y net income/share CAGR similar to VET's 158.97%. Walter Schloss might see both on parallel mid-term trajectories.
68.83%
Below 50% of VET's 193.59%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
199.38%
10Y equity/share CAGR at 50-75% of VET's 367.11%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
217.43%
5Y equity/share CAGR above 1.5x VET's 92.42%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
78.34%
3Y equity/share CAGR 1.25-1.5x VET's 53.64%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
897.71%
Dividend/share CAGR of 897.71% while VET is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
1005.59%
Dividend/share CAGR of 1005.59% while VET is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
426.78%
3Y dividend/share CAGR above 1.5x VET's 11.70%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
25.45%
AR growth well above VET's 50.15%. Michael Burry fears inflated revenue or higher default risk in the near future.
41.01%
We show growth while VET is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
5.27%
Positive asset growth while VET is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
7.57%
75-90% of VET's 9.96%. Bill Ackman advocates improvements in profitability or buybacks to keep pace in net worth growth.
2.65%
We have some new debt while VET reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
44.31%
SG&A growth well above VET's 16.96%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.